Can you get 'clinical-like' data from a preclinical model?


CRO Services

Gubra CRO services

We are specialized in preclinical contract research services enabling pharmaceutical and biotechnology companies to make fast and solid data based decisions moving projects forward. Our services include preclinical studies in a wide variety of rodent models, which can be adapted according to the specific scientific question in focus. We have a very high availably of animals, which means we can start your study with short notice.

Our team of highly specialized scientists have extensive experience leading studies and solving complex scientific challenges. We handle the entire process in house from in vivo pharmacology, data processing (ex vivo assays, histology, stereology, RNA sequencing, bioinformatics etc.) to final presentation of data. We maintain a constant focus on providing solid data as well as completing projects on time, within budget and according to the highest scientific standards.

Get in touch

Please get in touch if you are interested in discussing how to get started with your study.

Michael Feigh

Principal scientist
+45 2382 9493

Get in touch

Contact us


Preclinical acute and chronic efficacy as well as mode of action studies in different animal models of type 1 and type 2 diabetes.

Read more


Preclinical efficacy studies in diet induced and biopsy-confirmed models of non-alcoholic steatohepatitis (NASH).

Read more


Preclinical acute and chronic efficacy as well as mode of action studies in diet-induced obese (DIO) models.

Read more

Gastrointestinal diseases

Preclinical efficacy and histological expertise to evaluate disease stages in gastrointestinal diseases.

Read more

“Gubra has succeeded in combining careful design, enlightened scientific methodology and rigorous attention to detail with timely reporting. This is a rare feat for a CRO, and one that sets Gubra apart from other organizations in this space.“

Michael Cowley
Head of Department of Physiology | Monash University

NASH review

Review of preclinical models of NASH discussing the advantages and limitations of current in vivo mouse models used in drug discovery for NASH.
Read more  |  See other publications 

Press Release

Find out more about the partner program between Boeringer Ingelheim Pharma and Gubra.

Read more

Gubra Insights

Subscribe and get latest science insights from Gubra.

Sign up


Hørsholm Kongevej 11B
2970 Hørsholm
+45 3152 ­2650